Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of povorcitinib in nonsegmental vitiligo
jRCT2061240023Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in nonsegmental vitiligo comparing Povorcitinib Dose A with Placebo → Povorcitinib Dose A (2 arms). Primary endpoint: F-VASI75 at Week 52. Started Sep 2024; status: active, not recruiting.
02
Drugs
povorcitinib
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on jRCT2061240023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240023.